1. Home
  2. JANX vs QDEL Comparison

JANX vs QDEL Comparison

Compare JANX & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$13.61

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$33.14

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JANX
QDEL
Founded
2017
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
JANX
QDEL
Price
$13.61
$33.14
Analyst Decision
Strong Buy
Hold
Analyst Count
12
6
Target Price
$59.18
$39.33
AVG Volume (30 Days)
2.0M
821.9K
Earning Date
02-26-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,000,000.00
$2,714,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.26
$19.50
52 Week High
$47.58
$46.24

Technical Indicators

Market Signals
Indicator
JANX
QDEL
Relative Strength Index (RSI) 32.69 61.97
Support Level $13.68 $32.09
Resistance Level $14.34 $34.45
Average True Range (ATR) 0.46 1.65
MACD 0.43 0.23
Stochastic Oscillator 33.33 70.50

Price Performance

Historical Comparison
JANX
QDEL

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

Share on Social Networks: